Announcement

Collapse
No announcement yet.

Res Sq . An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Res Sq . An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein


    Res Sq


    . 2020 May 20;rs.3.rs-30374.
    doi: 10.21203/rs.3.rs-30374/v1. Preprint
    An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein


    Fatemeh Ghafouri 1 , Reza Ahangari Cohan 2 , Farshid Noorbakhsh 3 , Hilda Samimi 3 , Vahid Haghpanah 3



    Affiliations

    Abstract

    Since the first appearance of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) in China on December 2019, the world has now witnessed the emergence of the SARS- CoV-2 outbreak. Therefore, due to the high transmissibility rate of virus, there is an urgent need to design and develop vaccines against SARS-CoV-2 to prevent more cases affected by the virus. In this study, a computational approach is proposed for vaccine design against the envelope (E) protein of SARS-CoV-2, which contains a conserved sequence feature. First, we sought to gain potential B-cell and T-cell epitopes for vaccine designing against SARS-CoV-2. Second, we attempted to develop a multi-epitope vaccine. Immune targeting of such epitopes could theoretically provide defense against SARS-CoV-2. Finally, we evaluated the affinity of the vaccine to major histocompatibility complex (MHC) molecules to stimulate the immune system response to this vaccine. We also identified a collection of B-cell and T-cell epitopes derived from E proteins that correspond identically to SARS-CoV-2 E proteins. The in-silico design of our potential vaccine against E protein of SARS-CoV-2 demonstrated a high affinity to MHC molecules, and it can be a candidate to make a protection against this pandemic event.

    Keywords: COVID-19 vaccine; Envelope (E) protein; In-silico; SARS-CoV-2.

Working...
X